A pipeline innovated by the global human crisis

Indivior is pioneering the development and discovery of treatment strategies for OUD, as well as exploring new therapies to potentially address the needs of people suffering from alcohol, stimulant and cannabis use disorders.

Indivior’s R&D has led to a range of daily and monthly treatment options for patients with moderate-to -severe opioid use disorder. We also developed a monthly treatment option for the treatment of schizophrenia in adult patients.

To learn more about our commercially launched products, please visit the products page.


Brand Name/Product Candidate


Phase 1

Phase 2

Phase 3

Regulatory Approval

Commercial Launch

    Treatment of Cannabis Use Disorder

    AEF0117* Cannabinoid-1 receptor synthetic signaling specific inhibitor

    Treatment of Opioid Use Disorder

    INDV-6001** is a sustained-release LAI prodrug of buprenorphine

    Treatment for Opioid Use Disorder

    INDV-2000 selective orexin-1 receptor antagonist

    Treatment for Alcohol Use Disorder

    INDV-1000*** Gamma-aminobutyric acid subtype B (GABAB) positive allosteric modulator (PAM)

    Treatment for Acute Cannabinoid Overdose

    INDV-5004@ cannabinoid-1 receptor antagonist